TD Cowen upgraded Sana Biotechnology (SANA) to Buy from Hold without a price target The company reported positive data indicating Hypoimmune modified cadaver islet cells sustained immune evasion/C-peptide production in a type 1 diabetes patient without immunosuppression, the analyst tells investors in a research note. The firm says this establishes proof of concept for Hypoimmune’s immune evasion properties and “meaningfully derisks” type 1 diabetes and other applications. Much commercialization work remains ahead, but the company “now bears a meaningfully changed risk profile,” contends TD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results
- Sana Biotechnology up 285% afterhours following type 1 diabetes study data
- Sana Biotechnology announces initial results from type 1 diabetes study
- Sana Biotechnology price target lowered to $7 from $8 at BofA
- Sana Biotechnology announces Fast Track designation for SC291
Questions or Comments about the article? Write to editor@tipranks.com